Yingzhong Li · Q1 response · repeat-dosing immune effects (hedge)

5/16 Antibody Conference Q&A session · Q1 (audience question about oncolytic virus + repeat-dosing concern · per user m624 canonical sunvax.md grade A + yingzhong-li.md). Yingzhong's response captures the highest-value missing dataset signal (per HANDOFF_TO_m623 signal-3 "repeat…

Type

quote

Domain

conference

Grade

conference

License

LIGHT_HOPE_proprietary

Provenance

m622_command_round_12_batch_d_2026-05-17

evidence_grade

B

category

founder_panel_qa

status

draft

instance_tag

sunvax-antibody-2025

clinical_claim_softening

"founder hedged response on repeat-dosing immune effects · acknowledges data is incomplete · not intended to guide individual patient treatment choices"

quote_text

Yingzhong response key points (per panel transcript via user m624 canonical): - 单次注射数据 vs 临床重复给药外推不确定 - 重复给药可能 anti-capsid 抗体降低效力 - hedge: "we did a few tests" — 表示该数据未完整 - 不夸大 · 客观承认数据局限性

panel

Antibody_Conference_2026_05_15_Q1

topic

repeat_dosing_immune_effects

significance

Highest-value missing dataset per industry framing (HANDOFF_TO_m623 signal-3) · SunVax acknowledged repeat-dosing data is incomplete · represents both a science gap AND a client-conversation opportuni

speaker_name

Yingzhong Li

speaker_affiliation

SunVax mRNA Therapeutics Inc.

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.